Pages that link to "Q28088277"

The following pages link to The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development (Q28088277):

Displaying 11 items.

• Current and emerging treatment strategies for Duchenne muscular dystrophy (Q26741535) ‎ (← links)
• Looking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies (Q37589787) ‎ (← links)
• 'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases (Q37599234) ‎ (← links)
• Improving translational studies: lessons from rare neuromuscular diseases (Q43214157) ‎ (← links)
• Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease. (Q45951421) ‎ (← links)
• Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands. (Q55024154) ‎ (← links)
• Recommendations for the design of small population clinical trials (Q58608361) ‎ (← links)
• Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT) (Q89746817) ‎ (← links)
• Mouse models for muscular dystrophies: an overview (Q90733720) ‎ (← links)
• Moving neuromuscular disorders research forward: from novel models to clinical studies (Q90733732) ‎ (← links)
• A decade of optimizing drug development for rare neuromuscular disorders through TACT (Q92453720) ‎ (← links)